Biotechnology
HanAll Biopharma Reports First Quarter Results and Provides Business Update
* Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 * HanAll made a strong start to 2023 with positive Phase 3 study results of anti-FcRn asset batoclimab for the treatment of generalized myasthenia gravis in C...
2023-04-28 19:00
2958
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...
2023-04-28 14:43
2955
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
2023-04-28 08:58
2137
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...
2023-04-27 17:44
1813
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2023-04-26 22:15
3070
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of ul...
2023-04-26 21:16
2896
J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC
SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held inOrlando,...
2023-04-26 09:53
1661
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
* The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for theAsia-Pacific region, and globally * President Yoon Suk Yeol and First Lady Kim Keon Hee o...
2023-04-25 20:00
1506
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...
2023-04-25 13:46
1819
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System
SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...
2023-04-25 08:42
1848
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI, April 24, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), a leading gene and cell therapy CDMO inChina, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in theChina (Shang...
2023-04-24 22:36
2998
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 14.1% Year-Over-...
2023-04-24 18:03
2376
Samsung Biologics Reports First Quarter 2023 Financial Results
* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. * Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities. INCHEON, South Korea, April 24, 2023 /PRNews...
2023-04-24 14:51
2277
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI
* The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed * The latest preclinical data explored the antitumor efficacy and the intracranial activity of BBT-207 SEONGNAM, South Korea and CAMBRIDGE, Mass., April 23, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ...
2023-04-24 10:00
1649
ITRI Took Home Three Edison Awards(TM) in 2023
HSINCHU, April 21, 2023 /PRNewswire/ -- The highly-anticipated 2023 Edison
Awards™
2023-04-21 19:27
3147
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer
SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr.Oliver Kong as Chief Medical Officer (CMO). Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall c...
2023-04-21 09:06
2121
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CT041, an autologous CAR T-cell product candidate against the p...
2023-04-20 20:50
2397
CBC GROUP AND MUBADALA CO-LEAD US$315 MILLION FUNDRAISING ROUND FOR HASTEN BIOPHARMA
Proceeds raised will be used to fund future acquisitions, and fuel business development of innovative pipeline assets SINGAPORE, April 20, 2023 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm headquartered inSingapore, and Hasten Biopharmaceutic Company Lim...
2023-04-20 13:00
2220
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-20 08:00
1940
Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses
CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), announced today it has entered into a collaboration agreement w...
2023-04-19 08:45
2006
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
